Drug Decriminalization and Fatal Traffic Crashes: Evidence From BM110 in Oregon

IF 2.4 3区医学 Q2 ECONOMICS Health economics Pub Date : 2025-01-31 DOI:10.1002/hec.4944

Christian Gunadi, Yuyan Shi

{"title":"Drug Decriminalization and Fatal Traffic Crashes: Evidence From BM110 in Oregon","authors":"Christian Gunadi, Yuyan Shi","doi":"10.1002/hec.4944","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <p>Oregon Ballot Measure 110 (BM 110) reduced the penalties for non-commercial possession of a controlled substance, downgrading them from a felony or misdemeanor to a new Class E violation, punishable by a maximum $100 fine. In this paper, we investigate whether BM 110 was associated with changes in drug-related fatal traffic crashes in Oregon after its implementation in February 2021. To do so, we used Fatality Analysis Reporting System (FARS) data from 2018 to 2021 to calculate population-adjusted state-level drug-related fatal traffic crashes. We also employed a modified synthetic control method to create a “synthetic” Oregon, designed to closely resemble the state's pre-policy sociodemographic characteristics and outcome trends while correcting for time-invariant pre-policy differences. The findings show that BM 110 was not associated with changes in drug-related fatal traffic crashes per 100,000 population (0.114, 95% CI: −0.106, 0.334). These results suggest that the implementation of BM 110 did not change drug-related fatal traffic crashes in Oregon in the early period following its adoption.</p>\n </section>\n </div>","PeriodicalId":12847,"journal":{"name":"Health economics","volume":"34 5","pages":"815-820"},"PeriodicalIF":2.4000,"publicationDate":"2025-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health economics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hec.4944","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ECONOMICS","Score":null,"Total":0}

引用次数: 0

Abstract

Oregon Ballot Measure 110 (BM 110) reduced the penalties for non-commercial possession of a controlled substance, downgrading them from a felony or misdemeanor to a new Class E violation, punishable by a maximum $100 fine. In this paper, we investigate whether BM 110 was associated with changes in drug-related fatal traffic crashes in Oregon after its implementation in February 2021. To do so, we used Fatality Analysis Reporting System (FARS) data from 2018 to 2021 to calculate population-adjusted state-level drug-related fatal traffic crashes. We also employed a modified synthetic control method to create a “synthetic” Oregon, designed to closely resemble the state's pre-policy sociodemographic characteristics and outcome trends while correcting for time-invariant pre-policy differences. The findings show that BM 110 was not associated with changes in drug-related fatal traffic crashes per 100,000 population (0.114, 95% CI: −0.106, 0.334). These results suggest that the implementation of BM 110 did not change drug-related fatal traffic crashes in Oregon in the early period following its adoption.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

毒品合法化和致命交通事故：来自俄勒冈州BM110的证据。

俄勒冈州第110号投票法案（BM 110）减少了对非商业持有管制药物的处罚，将其从重罪或轻罪降级为新的E级违法行为，最高可处以100美元罚款。在本文中，我们调查了BM 110在2021年2月实施后是否与俄勒冈州与毒品相关的致命交通事故的变化有关。为此，我们使用了2018年至2021年的死亡分析报告系统（FARS）数据来计算经人口调整的州级毒品相关致命交通事故。我们还采用了一种改进的综合控制方法来创建一个“综合的”俄勒冈州，旨在与该州政策出台前的社会人口特征和结果趋势非常相似，同时纠正了政策出台前的时不变差异。研究结果表明，bm110与每10万人中与毒品相关的致命交通事故的变化无关（0.114,95% CI: -0.106, 0.334）。这些结果表明，bm110的实施并没有改变俄勒冈州在其采用后的早期与毒品有关的致命交通事故。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Health economics 医学-卫生保健

CiteScore

3.60

自引率

4.80%

发文量

177

审稿时长

4-8 weeks

期刊介绍： This Journal publishes articles on all aspects of health economics: theoretical contributions, empirical studies and analyses of health policy from the economic perspective. Its scope includes the determinants of health and its definition and valuation, as well as the demand for and supply of health care; planning and market mechanisms; micro-economic evaluation of individual procedures and treatments; and evaluation of the performance of health care systems. Contributions should typically be original and innovative. As a rule, the Journal does not include routine applications of cost-effectiveness analysis, discrete choice experiments and costing analyses. Editorials are regular features, these should be concise and topical. Occasionally commissioned reviews are published and special issues bring together contributions on a single topic. Health Economics Letters facilitate rapid exchange of views on topical issues. Contributions related to problems in both developed and developing countries are welcome.